625 related articles for article (PubMed ID: 26984605)
1. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
Cortese A; Vita G; Luigetti M; Russo M; Bisogni G; Sabatelli M; Manganelli F; Santoro L; Cavallaro T; Fabrizi GM; Schenone A; Grandis M; Gemelli C; Mauro A; Pradotto LG; Gentile L; Stancanelli C; Lozza A; Perlini S; Piscosquito G; Calabrese D; Mazzeo A; Obici L; Pareyson D
J Neurol; 2016 May; 263(5):916-924. PubMed ID: 26984605
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
Planté-Bordeneuve V; Gorram F; Salhi H; Nordine T; Ayache SS; Le Corvoisier P; Azoulay D; Feray C; Damy T; Lefaucheur JP
J Neurol; 2017 Feb; 264(2):268-276. PubMed ID: 27878441
[TBL] [Abstract][Full Text] [Related]
3. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S
J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161
[TBL] [Abstract][Full Text] [Related]
4. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
Lamb YN; Deeks ED
Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
[TBL] [Abstract][Full Text] [Related]
5. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy.
Gundapaneni BK; Sultan MB; Keohane DJ; Schwartz JH
Eur J Neurol; 2018 Mar; 25(3):464-468. PubMed ID: 29115008
[TBL] [Abstract][Full Text] [Related]
6. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
[TBL] [Abstract][Full Text] [Related]
7. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis.
Merlini G; Planté-Bordeneuve V; Judge DP; Schmidt H; Obici L; Perlini S; Packman J; Tripp T; Grogan DR
J Cardiovasc Transl Res; 2013 Dec; 6(6):1011-20. PubMed ID: 24101373
[TBL] [Abstract][Full Text] [Related]
8. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
Waddington Cruz M; Amass L; Keohane D; Schwartz J; Li H; Gundapaneni B
Amyloid; 2016 Sep; 23(3):178-183. PubMed ID: 27494299
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.
Coelho T; Maia LF; da Silva AM; Cruz MW; Planté-Bordeneuve V; Suhr OB; Conceiçao I; Schmidt HH; Trigo P; Kelly JW; Labaudinière R; Chan J; Packman J; Grogan DR
J Neurol; 2013 Nov; 260(11):2802-14. PubMed ID: 23974642
[TBL] [Abstract][Full Text] [Related]
10. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
[TBL] [Abstract][Full Text] [Related]
11. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy.
Amass L; Li H; Gundapaneni BK; Schwartz JH; Keohane DJ
Orphanet J Rare Dis; 2018 Dec; 13(1):225. PubMed ID: 30558645
[TBL] [Abstract][Full Text] [Related]
12. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
Shintani Y; Okada A; Morita Y; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Ohta-Ogo K; Kanzaki H; Ishibashi-Ueda H; Yasuda S; Shimazaki C; Yoshinaga T; Yazaki M; Sekijima Y; Izumi C
ESC Heart Fail; 2019 Feb; 6(1):232-236. PubMed ID: 30478886
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a case report].
Miyazaki Y
Nihon Ronen Igakkai Zasshi; 2017; 54(1):75-80. PubMed ID: 28202889
[TBL] [Abstract][Full Text] [Related]
14. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
Coelho T; Maia LF; Martins da Silva A; Waddington Cruz M; Planté-Bordeneuve V; Lozeron P; Suhr OB; Campistol JM; Conceição IM; Schmidt HH; Trigo P; Kelly JW; Labaudinière R; Chan J; Packman J; Wilson A; Grogan DR
Neurology; 2012 Aug; 79(8):785-92. PubMed ID: 22843282
[TBL] [Abstract][Full Text] [Related]
15. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy.
Lozeron P; Théaudin M; Mincheva Z; Ducot B; Lacroix C; Adams D;
Eur J Neurol; 2013 Dec; 20(12):1539-45. PubMed ID: 23834402
[TBL] [Abstract][Full Text] [Related]
16. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis.
Cárdenas-Soto K; Dominguez XH; Cortes G; Tsai F; Saniger MDM; Guraieb-Chahin P; Torres-Ocatvo B; Gibbons C; Kelly JW; Freeman R; González-Duarte A
J Peripher Nerv Syst; 2024 Jun; 29(2):221-231. PubMed ID: 38706223
[TBL] [Abstract][Full Text] [Related]
18. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
19. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
[No Abstract] [Full Text] [Related]
20. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis.
Damy T; Judge DP; Kristen AV; Berthet K; Li H; Aarts J
J Cardiovasc Transl Res; 2015 Mar; 8(2):117-27. PubMed ID: 25743445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]